Search Within

Carlyn Rose Tan

Formats
  1. Meeting Abstract (104)
  2. Journal Article (25)
  3. Research Letter (8)
  4. Correspondence (4)
  5. Review (3)
Groups
  1. Hematologic Malignancies, Division of (144)
  2. Department of Medicine (126)
  3. Center for Hematologic Malignancies (125)
  4. Myeloma (123)
  5. Survivorship Research (123)
  6. CTCR Scholars (122)

More Groups

People
  1. Alexander Lesokhin (121)
  2. Sham Mailankody (121)
  3. Urvi Shah (121)
  4. Malin Hultcrantz (120)
  5. Hani Hassoun (119)
  6. Neha Korde (119)

More People

Years
  1. 2025 (10)
  2. 2024 (44)
  3. 2023 (41)
  4. 2022 (29)
  5. 2021 (13)
  6. 2020 (7)
Publications
  1. Blood (54)
  2. Clinical Lymphoma, Myeloma and Leukemia (41)
  3. Journal of Clinical Oncology (9)
  4. Blood Cancer Journal (7)
  5. Blood Advances (5)
  6. American Journal of Hematology (4)

More Publications

Publishers
  1. American Society of Hematology (59)
  2. Elsevier Inc. (44)
  3. American Society of Clinical Oncology (9)
  4. Nature Publishing Group (9)
  5. John Wiley & Sons, Inc. (4)
  6. Taylor & Francis Group (3)

More Publishers

Results (144)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma
    Journal Article

    Costa, B. A.; Flynn, J.; Nishimura, N.; Devlin, S. M.; Farzana, T.; Rajeeve, S.; Chung, D. J.; Landau, H. J.; Lahoud, O. B.; Scordo, M.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta-analysis
    Journal Article

    Costa, B. A.; Costa, T. A.; Saravia, S. D.; Felix, N.; Tan, C. R.; Korde, N.; Richter, J.
    American Journal of Hematology (2024)

    Fulltext@MSK | Save
  • Progression-free survival of daratumumab versus bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: TAURUS chart review study
    Journal Article

    Gordan, L. N.; Tan, C. R.; Vescio, R.; Ye, J. C.; Schinke, C.; Medhekar, R.; Fu, A. Z.; Lafeuille, M. H.; Thompson-Leduc, P.; Khare, V.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups
    Journal Article

    Shah, U. A.; Moshier, E.; Derkach, A.; Huang, Y.; Mailankody, S.; Tan, C. R.; Maclachlan, K.; Hultcrantz, M.; Korde, N.; Hassoun, H.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Real-world patient profile and step-up dosing process of early initiators of teclistamab for multiple myeloma in US hospitals - An updated analysis using premier healthcare database
    Meeting Abstract

    Tan, C. R.; Kim, N.; Chinaeke, E.; Hester, L.; Fowler, J.; Gifkins, D.; Lin, D.; Walker, S.; Fu, A. Z.; Wu, B.
    Blood (2023)

    Fulltext@MSK | Save
  • Molecular monitoring with tumor DNA and nivolumab maintenance: A pilot study in diffuse large B-cell lymphoma
    Meeting Abstract

    Nakhoda, S.; Sklarz, T.; Pagan, C.; Matasar, M.; Messmer, M.; Frosch, Z. A. K.; Wang, Y. L.; Yanovsky, A. V.; Khanal, R.; Tan, C. R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) and daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C.; Maclachlan, K. H.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • T-cell exhaustion signature predicts early relapse after autologous stem cell transplant for multiple myeloma: BMT CTN 0702 secondary immune analysis
    Meeting Abstract

    Mehanna, N.; Derkach, A.; Gasmi, B.; Anagnostou, T.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Hassoun, H.; Maclachlan, K. H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Comprehensive genomic characterization of response and resistance to daratumumab-based quadruplet induction in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Maclachlan, K. H.; Tan, C. R.; Shekarkhand, T.; Rueda, C.; Serrano, E.; Nemirovsky, D.; Derkach, A.; McPherson, A.; Diamond, B.; Ziccheddu, B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • The complex structural variant chromothripsis can be defined on targeted sequencing panels, allowing direct clinical translation in order to improve multiple myeloma prognostication
    Meeting Abstract

    Maclachlan, K. H.; Ziccheddu, B.; Tan, C.; Shekarkhand, T.; Rueda, C.; Serrano, E.; Diamond, B.; Hassoun, H.; Mailankody, S.; Shah, U. A.; more...
    Blood (2023)

    Fulltext@MSK | Save